BNTX Analyst Ratings
BioNTech SE (BNTX) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $22.36B, listed on NASDAQ, employing roughly 7,807 people, carrying a beta of 1.25 to the broader market. BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. Led by Ugur Sahin, public since 2019-10-10.
Analyst Ratings
In the October 2026 monthly count, 22 analysts rated BNTX: 1 Strong Buy, 13 Buy, 7 Hold, 0 Sell and 1 Strong Sell.
Twelve months earlier, in October 2025: 21 analysts, 2 Strong Buy, 13 Buy, 6 Hold, 0 Sell and 0 Strong Sell.
Price Targets
- Average Target
- $120.33
- Median Target
- $123.00
- High
- $140.00
- Low
- $96.00
- Targets Published, Last 12 Months
- 20
Recent Price Targets
The 5 most recent of 20 price targets published in the last 12 months.
| Date | Firm | Analyst | Target | Price When Posted |
|---|---|---|---|---|
| Oct 14, 2026 | Canaccord Genuity | Not named | $132.00 | $89.01 |
| Oct 7, 2026 | Morgan Stanley | Terence Flynn | $114.00 | $95.63 |
| Sep 16, 2026 | Berenberg Bank | Not named | $140.00 | $96.69 |
| Sep 8, 2026 | BMO Capital | Evan David Seigerman | $105.00 | $103.76 |
| Aug 31, 2026 | Canaccord Genuity | Not named | $136.00 | $102.08 |
Recent Upgrades & Downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 14, 2026 | Canaccord Genuity | maintain | Buy | Buy |
| Oct 7, 2026 | Morgan Stanley | maintain | Overweight | Overweight |
| Sep 8, 2026 | BMO Capital | downgrade | Outperform | Market Perform |
| Aug 31, 2026 | Canaccord Genuity | maintain | Buy | Buy |
| Aug 5, 2026 | Evercore ISI Group | maintain | Outperform | Outperform |
Quantitative Rating
BNTX carries a model grade of B- (overall score 2 of 5), computed from six valuation and financial measures (discounted cash flow, return on equity, return on assets, debt to equity, price to earnings and price to book), each scored 1 to 5. It is not an analyst rating.
How to Read BNTX Analyst Coverage
Sell-side equity analysts publish three primary outputs: ratings (Strong Buy / Buy / Hold / Sell / Strong Sell, or firm-specific equivalents), price targets, and EPS / revenue estimate revisions. Rating consensus moves slowly relative to price; it reflects 12-month directional conviction rather than near-term momentum. Price targets are more responsive but typically drift behind realized price during sharp moves. The most actionable signal for options traders is a cluster of ratings actions across multiple firms within a short window, which compresses or expands implied volatility on a horizon of days to weeks and shifts the put-call skew toward the directional consensus. The recent-actions table above shows the five most recent firm-level changes; longer histories live behind aggregator sources.
For event-driven options sizing, pair the consensus rating and target distribution with the implied-volatility surface and dealer-positioning view. Aggressive target hikes from multiple firms tend to tighten put skew (downside protection becomes relatively cheaper); aggressive cuts widen put skew. The size of the IV response in the hours after a rating change is visible on the per-ticker volatility skew page and the gamma-exposure page, both of which show how dealer hedging propagates the analyst-driven flow into the listed options chain.
Learn how analyst ratings is reported and how to read the data →
Frequently asked BNTX analyst ratings questions
- What is the BNTX consensus price target?
- As of the latest aggregator update, BioNTech SE (BNTX) carries a consensus 12-month price target of $120.33. Target ranges run from a low of $96.00 to a high of $140.00. The target is the average of the price targets published by sell-side equity analysts covering the name.
- What is the analyst rating consensus on BNTX?
- In the October 2026 monthly count, 22 analysts rated BNTX, and the distribution tilts to the Buy side: 1 Strong Buy, 13 Buy, 7 Hold, 0 Sell and 1 Strong Sell. Rating consensus moves slowly relative to price; it reflects sell-side conviction over a 12-month horizon rather than near-term momentum.
- What recent ratings actions has BNTX seen?
- The five most recent ratings actions on BNTX appear on the page above. Sell-side rating changes are watched for two reasons: an upgrade or downgrade with a meaningful target revision moves the consensus and can trigger short-term positioning shifts, and the firm-level rating cluster (multiple firms moving in the same direction within a short window) is a clearer signal than any single action. Options markets often price the implied-vol response within minutes of the announcement.
- How do analyst targets affect BNTX options pricing?
- Analyst target revisions tend to be priced in by the lit options market within minutes of publication, but persistent target drift over weeks does correlate with implied-volatility movement. Aggressive target hikes from multiple firms inside a single quarter tighten put skew (downside protection becomes cheaper relative to upside speculation); aggressive cuts widen put skew. The most actionable read is the implied-vol response in the hours after a target change, which is visible on the per-ticker volatility skew page.